<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01564823</url>
  </required_header>
  <id_info>
    <org_study_id>APPRECIA</org_study_id>
    <nct_id>NCT01564823</nct_id>
  </id_info>
  <brief_title>Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease</brief_title>
  <acronym>APPRECIA</acronym>
  <official_title>Adalimumab on Preventing Postoperative Recurrence of Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Effice Servicios Para la Investigacion S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study objective is evaluate Adalimumab efficacy versus Azathioprine efficacy on
      prevention of endoscopic recurrence (Rutgeerts Index= 2b, 3 or 4) in Crohn´s Disease patients
      after 52 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of endoscopic recurrences</measure>
    <time_frame>52 weeks after the begin of the study</time_frame>
    <description>Evaluation of the effectiveness on prevention of endoscopic recurrence evaluated as changes in the Rutgeerts Index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Crohns´disease remission</measure>
    <time_frame>24 weeks</time_frame>
    <description>% of patients showing clinical remission after 24 and 52 weeks of adalimumab vs azathioprin treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of postsurgical recurrences</measure>
    <time_frame>52 week</time_frame>
    <description>Evaluation of the Adalimumab efficiency on preventing postsurgical recurrence with Magnetic Resonance Enterography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of hospitalized patients</measure>
    <time_frame>52 weeks</time_frame>
    <description>Comparing hospitalization percentage in patients using adalimumab or azathioprin after 52 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of activity markers</measure>
    <time_frame>24 weeks</time_frame>
    <description>Evaluating changes in markers such as reactive c-protein, variable surface glycoprotein , faecal calprotectin, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of surgeries</measure>
    <time_frame>Until 52 week</time_frame>
    <description>Comparing % of patients who needs surgery on Adalimumab vs Azatioprine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SIBDQ and EuroQOL indexes</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse event reports</measure>
    <time_frame>52 weeks</time_frame>
    <description>Comparison of safety of Adalimumab versus Azatioprine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Crohns´disease remission</measure>
    <time_frame>52 weeks</time_frame>
    <description>% of patients showing clinical remission after 24 and 52 weeks of adalimumab vs azatioprine treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of activity markers</measure>
    <time_frame>52 weeks</time_frame>
    <description>Evaluating changes in markers such as reactive c-protein, VSG, faecal calprotectine, etc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SIBDQ and EuroQOL indexes</measure>
    <time_frame>52 weeks</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Crohn´s Disease</condition>
  <arm_group>
    <arm_group_label>Metronidazole + Azathioprine.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metronidazole, oral intake. 250 mg/8h. 3 months. Azathioprine, 2.5 mg/weight kg/day, oral intake. All study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metronidazole + Adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metronidazole Oral Intake. 250 mg/8h. During 3 months. Adalimumab Subcutaneous 160 mg and 80 mg 2wk. Then 40 mg during 2wk as maintenance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Metronidazole: 250 mg/8h. 3 months.</description>
    <arm_group_label>Metronidazole + Azathioprine.</arm_group_label>
    <other_name>Flagyl (Metronidazole)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Metronidazole 250 mg/8h 3 months</description>
    <arm_group_label>Metronidazole + Adalimumab</arm_group_label>
    <other_name>Flagyl (Metronidazole)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <description>Azathioprine: 2.5 mg/kg of weight/day. 3 months.</description>
    <arm_group_label>Metronidazole + Azathioprine.</arm_group_label>
    <other_name>Imurel (Azathioprine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.</description>
    <arm_group_label>Metronidazole + Adalimumab</arm_group_label>
    <other_name>Humira (Adalimumab)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years of age at the time of signing informed consent.

          -  Patients with Crohn's disease who have undergone an ileocecal/ileocolic resection (L1
             or L3). The study and the treatment must be initiated within the two first weeks after
             the resection (+/- 5 days).

          -  Patients with surgical reconstruction by ileocolic anastomosis.

          -  Women of childbearing age must not be breastfeeding and must have a negative urine
             pregnancy test and must agree to use contraceptive methods with a &lt;1% failure rate
             (e.g., sexual abstinence, oral contraceptives, double barrier methods, intrauterine
             devices), unless they only have one partner who is sterile.

          -  Patients who have signed and dated the informed consent form before performing any
             specific screening study procedure.

        Exclusion Criteria:

          -  Resection that requieres Temporal ileostomy.

          -  Urgency resection which doesn´t permit the initial assessment protocol completion.

          -  Resection due to inactive short indolent stenosis (&lt;10 cm).

          -  Resection with mucosal macroscopic residual disease in anastomosis.

          -  Previous intolerance or adverse reaction (moderate or severe) to adalimumab or
             azathioprine.

          -  Any contraindications or unwillingness to perform the scheduled colonoscopies or
             resonances.

          -  Contraindications to Adalimumab treatment, among which the following are included:
             active tuberculosis, severe infections such as sepsis or opportunistic infections,
             moderate or severe heart failure (NYHA class III or IV), central nervous system
             demyelinating diseases, history of malignant neoplasm or autoimmune diseases.

          -  Severe associated Extraintestinal manifestations.

          -  Previous postoperative recurrence prevention treatments with adalimumab, asathiprine o
             mercaptopurine which resulted in failure.

          -  Any other disease or patient condition that according to investigator criteria,
             inadequates patient´s participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pilar Nos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari i Politecnic La Fe (Valencia, Spain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Mutua de Terrasa</name>
      <address>
        <city>Terrasa</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerto Real</name>
      <address>
        <city>Puerto Real</city>
        <state>Cádiz</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Dr. Negrín</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Islas Canarias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide</name>
      <address>
        <city>Ferrol</city>
        <state>La Coruña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Manises</name>
      <address>
        <city>Manises</city>
        <state>Valencia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Doce de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Policlinic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Río Hortega</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2012</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2012</study_first_posted>
  <last_update_submitted>March 15, 2015</last_update_submitted>
  <last_update_submitted_qc>March 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn´s disease</keyword>
  <keyword>Metronidazole</keyword>
  <keyword>Azathioprine</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>post-chirurgic recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

